ReviewCardiovascular therapeutics2022
Apolipoprotein A1-Related Proteins and Reverse Cholesterol Transport in Antiatherosclerosis Therapy: Recent Progress and Future Perspectives.
Review in Cardiovascular therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 45 citations in OpenAlex.
- Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy.Drug delivery · 2026Article
- CRISPR/dCas9-induced upregulation of endogenous apolipoprotein A1 and paraoxonase 1 genes reduces the aortic lipid deposits in apoEMolecular biomedicine · 2026Article
- Systemic Metabolic Changes in Plasma of Patients with Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia.Metabolites · 2026Article
- Beneficial Changes in Apolipoprotein Concentrations After Bariatric Surgery in Obese Women.Metabolites · 2026Article
- Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026Article
- Article
- Liver transcriptome dynamics in Holstein cows during the periparturient transition.Scientific reports · 2026Article
- Article
- Transcriptome and DNA methylation responses in the liver of Megalobrama amblycephala under hypoxia and heat stress.Fish physiology and biochemistry · 2026Article
- Recent Updates on the Role of Genetic and Epigenetic Factors in the Pathogenesis of the Metabolic Syndrome.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Serum lipid profiles and risk of depression: a UK Biobank prospective cohort study.Frontiers in nutrition · 2026Article
- Associations of non-traditional lipid parameters with high-risk plaques characterized by optical coherence tomography in acute myocardial infarction culprit lesions.Frontiers in cardiovascular medicine · 2026Article
- Associations of apolipoprotein A1, apolipoprotein B, and their ratio with novel cardiometabolic indices in adults with coronary artery disease.Frontiers in cardiovascular medicine · 2026Article
- Serum Amyloid A (SAA) and Its Interaction with High-Density Lipoprotein Cholesterol (HDL-C): A Comprehensive Review.International journal of molecular sciences · 2025Review
- Synergistic taurine and methionine supplementation enhances growth and cholesterol regulation in Totoaba macdonaldi.Fish physiology and biochemistry · 2025Article
- Changes in Apolipoprotein A1-Associated Proteomic Composition After Pioglitazone Treatment Versus Weight Loss.International journal of molecular sciences · 2025Article
- Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets.Molecular biomedicine · 2025Review
- Phytogenic feed additive derived fromOpen veterinary journal · 2025Article
- HDLR-SR-BI Expression and Cholesterol Uptake are Regulated via Indoleamine-2,3-dioxygenase 1 in Macrophages under Inflammation.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Novel treatment of acute and acute-on-chronic liver failure: Interleukin-22.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperlipidemia characterized by abnormal deposition of cholesterol in arteries can cause atherosclerosis and coronary artery occlusion, leading to atherosclerotic coronary heart disease. The body prevents atherosclerosis by reverse cholesterol transport to mobilize and excrete cholesterol and other lipids. Apolipoprotein A1, the major component of high-density lipoprotein, plays a key role in reverse cholesterol transport. Here, we reviewed the role of apolipoprotein A1-targeting molecules in antiatherosclerosis therapy, in particular ATP-binding cassette transporter A1, lecithin-cholesterol acyltransferase, and scavenger receptor class B type 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.